A Prospective Study on Optimizing Treatment for ABPA

• Status: Not yet recruiting
• Trial end date: 2023-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to evaluate the efficacy of treatment using oral glucocorticoid, anti-fungal agent, anti-IgE mAb for patient with ABPA.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Treatments: Itraconazole; Omalizumab; Prednisone

Criteria

Inclusion Criteria:

• 18~75 years old, male or female

• associated past medical history, including asthma, bronchiectasis, COPD ect.

• elevated serum total IgE (>100IU/mL)

• elevated aspergillus specific IgE

Exclusion Criteria:

• According to the investigator, the patient has other factors that may affect the results of the study or lead to the termination of the study, such as alcohol abuse, drug abuse, other serious diseases (including mental illness).

• Pregnancy or breastfeeding

• Abnormality of liver or kidney function